We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+14.89%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.59B
AUM Growth
+$163M
Cap. Flow
-$639M
Cap. Flow %
-24.64%
Top 10 Hldgs %
35.1%
Holding
118
New
11
Increased
13
Reduced
28
Closed
12

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$84.6M
2
MCK icon
McKesson
MCK
+$33.5M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$32.2M
4
LOXO
Loxo Oncology, Inc
LOXO
+$20.7M
5
BHC icon
Bausch Health
BHC
+$20.6M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$102M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$61.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$46.5M
4
NVRO
NEVRO CORP.
NVRO
+$31.5M
5
HUM icon
Humana
HUM
+$26.6M

Sector Composition

Rank Sector Weight
1 Healthcare 71.12%
2 Financials 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPCH icon
76
Option Care Health
OPCH
$3.41B
$3.35M 0.13%
492,807
– –
AGRX
77
DELISTED
Agile Therapeutics
AGRX
$3.11M 0.12%
486
+287
+144% +$1.44M
GNCA
78
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.92M 0.11%
59,875
-26,032
-30% -$1.02M
SCYX icon
79
SCYNEXIS
SCYX
$42.4M
$2.89M 0.11%
13,100
– –
ADPT
80
DELISTED
Adeptus Health Inc
ADPT
$2.88M 0.11%
1,600,861
– –
CASM
81
DELISTED
CAS Medical Systems, Inc.
CASM
$2.61M 0.1%
1,798,434
-1,401,566
-44% -$2.13M
EYPT icon
82
EyePoint Inc
EYPT
$1.12B
$2.57M 0.1%
149,282
– –
TARA icon
83
Protara Therapeutics
TARA
$230M
$2.33M 0.09%
33,315
– –
TVTY
84
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$2.21M 0.09%
76,000
– –
VYGR icon
85
Voyager Therapeutics
VYGR
$192M
$1.56M 0.06%
117,647
-117,647
-50% -$1.43M
MTEM
86
DELISTED
Molecular Templates, Inc.
MTEM
$1.25M 0.05%
13,346
– –
CRVS icon
87
Corvus Pharmaceuticals
CRVS
$1.25B
$767K 0.03%
+36,931
New +$578K
STRM
88
DELISTED
Streamline Health Solutions
STRM
$676K 0.03%
44,198
– –
SNDX icon
89
Syndax Pharmaceuticals
SNDX
$2.02B
$523K 0.02%
+38,130
New +$396K
HIND
90
Vyome Holdings
HIND
$15.1M
– –
0
– –
ATXS
91
DELISTED
Astria Therapeutics
ATXS
– –
-11,382
Closed -$2.46M
CLDX icon
92
Celldex Therapeutics
CLDX
$2.77B
– –
-42,196
Closed -$2.24M
EXAS
93
DELISTED
Exact Sciences
EXAS
– –
-500,000
Closed -$6.68M
IONS icon
94
Ionis Pharmaceuticals
IONS
$8.99B
– –
-214,095
Closed -$10.2M
ZBH icon
95
Zimmer Biomet
ZBH
$17.6B
– –
-154,500
Closed -$15.5M
KA
96
DELISTED
Kineta, Inc. Common Stock
KA
– –
-1,329
Closed -$2.28M
PRTK
97
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-100,000
Closed -$1.54M
GBT
98
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-171,428
Closed -$2.48M
NVLN
99
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
– –
-170,454
Closed -$1.44M
KERX
100
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-1,291,531
Closed -$7.57M
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2017 Portfolio in Review

As of Q1 2017, Deerfield Management held 118 positions worth $2.59B, up 6.7% from $2.43B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management withdrew a net $639M in Q1 2017, closing 12 positions and reducing 28 holdings. Its most notable exit was Zimmer Biomet, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 69% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Gilead Sciences worth $81.7M.

  • Deerfield Management's largest Q1 2017 buy was Gilead Sciences: 1,203,000 shares worth $81.7M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017, an estimated $32.2M increase.
  • Deerfield Management's biggest Q1 2017 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $102M.
  • Deerfield Management fully exited Zimmer Biomet in Q1 2017, selling an estimated $15.5M.
  • Deerfield Management's ten largest holdings make up 35% of its $2.59B portfolio in Q1 2017.
  • Deerfield Management opened 11 new positions and closed 12 in Q1 2017.
  • Deerfield Management's portfolio value rose 6.7% quarter-over-quarter to $2.59B.

Based on Deerfield Management's 13F filing for Q1 2017, filed 15 May 2017.